A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence

Mason, R. Preston
December 2005
Current Drug Targets - Cardiovascular & Haematological Disorders;Dec2005, Vol. 5 Issue 6, p489
Academic Journal
Calcium channel blockers and HMG-CoA reductase inhibitors are widely used for the management of hypertension and dyslipidemia, respectively. The use of these agents in the prevention and treatment of cardiovascular disease remains largely based on their actions in lowering blood pressure and lipids. Recent clinical trials, however, indicate that certain members of these two drug classes may slow progression of disease to an extent that cannot be solely attributed to risk factor reduction. The proposed mechanisms for such pleiotropic actions include enhancement of endothelial-dependent nitric oxide bioavailability, anti-inflammatory activity, and inhibition of oxidative stress. To understand the basis for such effects, along with potential synergies, we will review the basic and clinical evidence that indicate a broader opportunity for treatment and protection of cardiovascular events by atheroprotection with these agents beyond risk factor management.


Related Articles

  • The Role of C-Reactive Protein (CRP) and Statin Treatment in Reducing Cardiovascular Risk. Chin, Jaclynn // South Dakota Medicine;2009, p104 

    The article explains the role of C-reactive protein (CRP) and statin treatment in lowering cardiovascular risk. CRP is said to be the primary inflammatory predictor of future coronary heart disease (CHD) events. Health professionals from the U.S. Centers for Disease Control (CDC) and the...

  • Synergistic Effect of Amlodipine and Atorvastatin in Reversing LDL-Induced Endothelial Dysfunction. Ruslan Kubant; Gehan Heeba; Robert Jacob; Charles Day; Yehudi Medlin; Tadeusz Malinski // Pharmaceutical Research;Aug2008, Vol. 25 Issue 8, p1798 

    Abstract Purpose  Statins and certain calcium channel blockers may improve nitric oxide (NO) release and endothelial function through various mechanisms, but their combined effects are not well understood. Methods  The separate versus combined effects of amlodipine (AML) and...

  • Results from the ACCORD Lipid Study.  // MD Conference Express;May2010, p11 

    The article discusses the results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study, which was presented in the American College of Cardiology (ACC) 59th Annual Scientific Session. It says that the ACCORD Lipid Study does not encourage the use of combined statin and...

  • Smanjenje tereta koronarne bolesti srca na dokazima utemeljenim principima liječenja. Meško, Jasna; Hribar, Veronika; Brus, Sanja; Grošelj, Mateja; Barbič-Žagar, Breda // Cardiologia Croatica;Jan/Feb2014, Vol. 9 Issue 1/2, p76 

    Coronary heart disease (CHD) is the leading cause of death worldwide. Unfortunately, sudden cardiac death is for many individuals the first manifestation of CHD. Prevention ideally begins with primary interventions in persons at increased risk for cardiovascular disease (CVD) but without...

  • Early initiation of statins following ACS does not improve outcomes.  // Journal of Family Practice;Aug2006, Vol. 55 Issue 8, p664 

    The article presents a study on whether early initiation of statins following the onset of acute coronary syndromes (ACS) will reduce the short-term risk of death, recurrent myocardial infarction or stroke. The study was carried out through meta-analysis of randomized controlled trials. The...

  • INFOGRAPHIC. Road to Heart Disease.  // Good Medicine;Summer2015, Vol. 24 Issue 3, p23 

    The article presents an information graphic related to the risk of heart disease in obese children.

  • Vascular Pleiosynergy - Does It Really Work? Cs�sz�r, Albert // Current Vascular Pharmacology;Oct2007, Vol. 5 Issue 4, p302 

    Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic...

  • Statins bring long-term falls in non-CVD disease. Anekwe, Lilian // Pulse;9/7/2011, Vol. 71 Issue 28, p15 

    The article reports on the result of a study conducted by researchers in Great Britain, which shows that long-term intake of statins decreases the risk of non-fatal myocardial infarction and fatal coronary heart disease (CHD).

  • Antidote. SIEGEL // Medical Marketing & Media;Dec2008, Vol. 43 Issue 12, p14 

    The article presents the author's comment on Jupiter, one of many crucial antidotes against the irrational fear of lifesaving statins. According to the author, Jupiter trial is the first big study looking at giving a statin to more than 17,000 healthy men and women with an LDL cholesterol lower...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics